A systematic review of trials of PCSK9‐inhibiting antibodies to quantify the incidence of cancer associated with their use reported an odds ratio of 0.88 (95% confidence interval [CI], 0.61–1.18) and concluded there was no effect on cancer diagnosis.26 This evidence concerns the gene PCSK9 and cancer.